Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Children's National Research Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05302921CT.gov Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ewing Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Children's National Research Institute | P2 | B · 57 |
| Irinotecan | Milton S. Hershey Medical Center | P3 | BB |
| Nivolumab | Children's National Research Institute | P2 | B |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Nogitecan | Pfizer | P2 | B |
| Adriamycin | Children's National Research Institute | P2 | B |
| Nadravaleucel | Brenda Cooper, MD | P2 | B |
| PI3K/MTOR INHIBITOR LY3023414 | National Cancer Institute (NCI) | P2 | B |
| Gemogenovatucel-T | Gradalis, Inc. | P3 | B |
+42 more in the Ewing Sarcoma cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Ewing Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-ewing-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →